Here are some of the drugs that are predicted to become blockbusters in the next few years, according to Clarivate's latest ...

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

Novo Nordisk, PepsiCo, Cencora, and Lemonade. CBP seizes rocket launcher at Arizona port 5 Expenses Parents Should Stop ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

President-elect Trump threatens tariffs on Denmark for Greenland bid, impacting Danish stocks. Read more here.

North Dakota lawmakers on Thursday will hear testimony on a bill to lower the price of insulin drugs and supplies for ...

After holding leadership positions at contract manufacturers Patheon and Thermo Fisher Scientific, working in the food and ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

Novo Nordisk partners with Variant Bio, paying up to $50M upfront for metabolic disease targets. Some funds will support Indigenous communities that provided data.

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...